Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 82

1.

Molecular mechanisms involved in epidermal growth factor receptor-mediated inhibition of dopamine D3 receptor signaling.

Sun N, Zhang X, Guo S, Le HT, Zhang X, Kim KM.

Biochim Biophys Acta Mol Cell Res. 2018 Sep;1865(9):1187-1200. doi: 10.1016/j.bbamcr.2018.06.001. Epub 2018 Jun 7.

PMID:
29885323
2.

BACE1-Dependent Neuregulin-1 Signaling: An Implication for Schizophrenia.

Zhang Z, Huang J, Shen Y, Li R.

Front Mol Neurosci. 2017 Sep 25;10:302. doi: 10.3389/fnmol.2017.00302. eCollection 2017. Review.

3.

Epidermal growth factor signals attenuate phenotypic and functional development of neocortical GABA neurons.

Namba H, Nagano T, Jodo E, Eifuku S, Horie M, Takebayashi H, Iwakura Y, Sotoyama H, Takei N, Nawa H.

J Neurochem. 2017 Jun 13. doi: 10.1111/jnc.14097. [Epub ahead of print]

4.

The EGF receptor inhibits the signaling of dopamine D3 receptor through the phosphorylation of GRK2 on tyrosine residues.

Sun N, Zhang X, Zhang X, Kim KM.

Biochem Biophys Res Commun. 2017 Aug 5;489(4):515-522. doi: 10.1016/j.bbrc.2017.05.183. Epub 2017 Jun 1.

PMID:
28579429
5.

Neuregulin1 alpha activates migration of neuronal progenitors expressing ErbB4.

Fornasari BE, El Soury M, De Marchis S, Perroteau I, Geuna S, Gambarotta G.

Mol Cell Neurosci. 2016 Dec;77:87-94. doi: 10.1016/j.mcn.2016.10.008. Epub 2016 Oct 27.

PMID:
27989735
6.

Decline in Proliferation and Immature Neuron Markers in the Human Subependymal Zone during Aging: Relationship to EGF- and FGF-Related Transcripts.

Weissleder C, Fung SJ, Wong MW, Barry G, Double KL, Halliday GM, Webster MJ, Weickert CS.

Front Aging Neurosci. 2016 Nov 25;8:274. eCollection 2016.

7.

Inflammatory, cardio-metabolic and diabetic profiling of chronic schizophrenia.

Balõtšev R, Koido K, Vasar V, Janno S, Kriisa K, Mahlapuu R, Ljubajev U, Parksepp M, Veiksaar P, Volke V, Lang A, Haring L, Zilmer M, Vasar E.

Eur Psychiatry. 2017 Jan;39:1-10. doi: 10.1016/j.eurpsy.2016.05.010. Epub 2016 Nov 1.

PMID:
27810612
8.

Growth factors as clinical biomarkers of prognosis and diagnosis in psychiatric disorders.

Galvez-Contreras AY, Campos-Ordonez T, Lopez-Virgen V, Gomez-Plascencia J, Ramos-Zuniga R, Gonzalez-Perez O.

Cytokine Growth Factor Rev. 2016 Dec;32:85-96. doi: 10.1016/j.cytogfr.2016.08.004. Epub 2016 Sep 8. Review.

PMID:
27618303
9.

Taurine and Epidermal Growth Factor Belong to the Signature of First-Episode Psychosis.

Koido K, Innos J, Haring L, Zilmer M, Ottas A, Vasar E.

Front Neurosci. 2016 Jul 15;10:331. doi: 10.3389/fnins.2016.00331. eCollection 2016.

10.

Proteolytic processing of Neuregulin-1.

Willem M.

Brain Res Bull. 2016 Sep;126(Pt 2):178-182. doi: 10.1016/j.brainresbull.2016.07.003. Epub 2016 Jul 5. Review.

PMID:
27393467
11.

Striatal but not frontal cortical up-regulation of the epidermal growth factor receptor in rats exposed to immune activation in utero and cannabinoid treatment in adolescence.

Idrizi R, Malcolm P, Weickert CS, Zavitsanou K, Suresh Sundram.

Psychiatry Res. 2016 Jun 30;240:260-264. doi: 10.1016/j.psychres.2016.04.026. Epub 2016 Apr 18.

PMID:
27138815
12.

Cortical gray matter loss in schizophrenia: Could microglia be the culprit?

Rački V, Petrić D, Kučić N, Gržeta N, Jurdana K, Rončević-Gržeta I.

Med Hypotheses. 2016 Mar;88:18-21. doi: 10.1016/j.mehy.2015.12.021. Epub 2016 Jan 9.

PMID:
26880628
13.

Assessment of a multi-assay biological diagnostic test for mood disorders in a Japanese population.

Yamamori H, Ishima T, Yasuda Y, Fujimoto M, Kudo N, Ohi K, Hashimoto K, Takeda M, Hashimoto R.

Neurosci Lett. 2016 Jan 26;612:167-171. doi: 10.1016/j.neulet.2015.12.019. Epub 2015 Dec 11.

PMID:
26687272
14.

Neuregulin 1 expression and electrophysiological abnormalities in the Neuregulin 1 transmembrane domain heterozygous mutant mouse.

Long LE, Anderson P, Frank E, Shaw A, Liu S, Huang XF, Pinault D, Karl T, O'Brien TJ, Shannon Weickert C, Jones NC.

PLoS One. 2015 May 19;10(5):e0124114. doi: 10.1371/journal.pone.0124114. eCollection 2015.

15.

Neurobehavioral Differences Between Mice Receiving Distinct Neuregulin Variants as Neonates; Impact on Sensitivity to MK-801.

Kato T, Abe Y, Hirokawa S, Iwakura Y, Mizuno M, Namba H, Nawa H.

Curr Mol Med. 2015;15(3):222-36.

16.

Disruption of the ErbB signaling in adolescence increases striatal dopamine levels and affects learning and hedonic-like behavior in the adult mouse.

Golani I, Tadmor H, Buonanno A, Kremer I, Shamir A.

Eur Neuropsychopharmacol. 2014 Nov;24(11):1808-18. doi: 10.1016/j.euroneuro.2014.09.011. Epub 2014 Oct 2.

PMID:
25451700
17.

Transient overexposure of neuregulin 3 during early postnatal development impacts selective behaviors in adulthood.

Paterson C, Law AJ.

PLoS One. 2014 Aug 5;9(8):e104172. doi: 10.1371/journal.pone.0104172. eCollection 2014.

18.

Integrative proteomic analysis of the NMDA NR1 knockdown mouse model reveals effects on central and peripheral pathways associated with schizophrenia and autism spectrum disorders.

Wesseling H, Guest PC, Lee CM, Wong EH, Rahmoune H, Bahn S.

Mol Autism. 2014 Jul 4;5:38. doi: 10.1186/2040-2392-5-38. eCollection 2014.

19.

Neuropathologic implication of peripheral neuregulin-1 and EGF signals in dopaminergic dysfunction and behavioral deficits relevant to schizophrenia: their target cells and time window.

Nawa H, Sotoyama H, Iwakura Y, Takei N, Namba H.

Biomed Res Int. 2014;2014:697935. doi: 10.1155/2014/697935. Epub 2014 May 13. Review.

20.

Ablation of ErbB4 from excitatory neurons leads to reduced dendritic spine density in mouse prefrontal cortex.

Cooper MA, Koleske AJ.

J Comp Neurol. 2014 Oct 1;522(14):3351-62. doi: 10.1002/cne.23615. Epub 2014 Apr 29.

Supplemental Content

Loading ...
Support Center